{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:40:39Z","timestamp":1740148839691,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13071-019-3690-6","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T10:04:13Z","timestamp":1567764253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety of an extended-release injectable moxidectin suspension formulation (ProHeart\u00ae 12) in dogs"],"prefix":"10.1186","volume":"12","author":[{"given":"Matthew J.","family":"Krautmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Mahabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Fielder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Collard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracie L.","family":"Wolthuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Esch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent","family":"Alleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laibin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"McCandless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Nederveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Kryda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"3690_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s13071-019-3632-3","volume":"12","author":"TL McTier","year":"2019","unstructured":"McTier TL, Kryda K, Wachowski M, Mahabir S, Ramsey D, Rugg D, et al. ProHeart\u00ae 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months. Parasites Vectors. 2019;12:369.","journal-title":"Parasites Vectors."},{"key":"3690_CR2","volume-title":"Investigation of the effects of gamma irradiation on glyceryl tristearate","author":"K Alleman","year":"2015","unstructured":"Alleman K. Investigation of the effects of gamma irradiation on glyceryl tristearate. Kalamazoo: Zoetis; 2015."},{"key":"3690_CR3","first-page":"1","volume-title":"Pharmaceutical Science Report on ProHeart\u00ae 6\/12 CVM comments","author":"L Luo","year":"2014","unstructured":"Luo L. Pharmaceutical Science Report on ProHeart\u00ae 6\/12 CVM comments. Kalamazoo: Zoetis Veterinary Medicine R&D; 2014. p. 1."},{"key":"3690_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/bdd.313","volume":"23","author":"S Vanapalli","year":"2002","unstructured":"Vanapalli S, Hung Y-P, Fleckenstein L, Dzimianski M, McCall J. Pharmacokinetics and dose proportionality of oral moxidectin in beagle dogs. Biopharm Drug Dispos. 2002;23:263\u201372.","journal-title":"Biopharm Drug Dispos."},{"key":"3690_CR5","unstructured":"Freedom of Information Summary NADA 141-051: ProHeart\u2122 for dogs. Center for Veterinary Medicine, U.S. Food and Drug Administration; 1997."},{"key":"3690_CR6","volume-title":"Twenty-four hour moxidectin blood profile at or near steady state in dogs receiving a diet containing 45 ppm moxidectin for 28 consecutive days","author":"RL DeLay","year":"2006","unstructured":"DeLay RL. Twenty-four hour moxidectin blood profile at or near steady state in dogs receiving a diet containing 45 ppm moxidectin for 28 consecutive days. Princeton: Fort Dodge Animal Health; 2006."},{"key":"3690_CR7","volume-title":"Comparison of serum levels and injection site irritation following subcutaneous injection of 10% moxidectin GTS microsphere injectable formulations in beagles","author":"M Doscher","year":"1999","unstructured":"Doscher M. Comparison of serum levels and injection site irritation following subcutaneous injection of 10% moxidectin GTS microsphere injectable formulations in beagles. Princeton: Fort Dodge Animal Health, Division of Wyeth; 1999."},{"key":"3690_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/all.12350","volume":"69","author":"P Demoly","year":"2014","unstructured":"Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy. 2014;69:420\u201337.","journal-title":"Allergy."},{"key":"3690_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaci.2012.11.017","volume":"132","author":"S Johansson","year":"2013","unstructured":"Johansson S, Ad\u00e9doyin J, van Hage M, Gr\u00f6nneberg R, Nopp A. False-positive penicillin immunoassay: an unnoticed common problem. J Allergy Clin Immunol. 2013;132:235\u20137.","journal-title":"J Allergy Clin Immunol."},{"key":"3690_CR10","volume-title":"Textbook of adverse drug reactions","author":"MD Rawlins","year":"1977","unstructured":"Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Glasgow: Oxford University Press; 1977."},{"key":"3690_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jaci.2013.11.013","volume":"133","author":"S Sicherer","year":"2014","unstructured":"Sicherer S, Leung D. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2013. J Allergy Clin Immunol. 2014;133:324\u201334.","journal-title":"J Allergy Clin Immunol."},{"key":"3690_CR12","unstructured":"Guide for the care and use of laboratory animals. Washington DC: National Academies Press; 2011."},{"key":"3690_CR13","unstructured":"CVMP\/VICH\/393388\/2006. VICH GL43: Target animal safety for veterinary pharmaceutical products. Brussels: International Federation for Animal Health; 2009."},{"key":"3690_CR14","volume-title":"Appraisal of the safety of chemicals in foods, drugs, and cosmetics","author":"JH Draize","year":"1959","unstructured":"Draize JH. Appraisal of the safety of chemicals in foods, drugs, and cosmetics. Austin: Association of Food & Drug Officials of the United States; 1959."},{"key":"3690_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/01926230490268756","volume":"32","author":"J Crissman","year":"2004","unstructured":"Crissman J, Goodman D, Hildebrandt P, Maronpot R, Prater D, Riley J, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol. 2004;32:126\u201331.","journal-title":"Toxicol Pathol."},{"key":"3690_CR16","volume-title":"The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions (E1)","author":"CPMP\/ICH\/286\/95","year":"1994","unstructured":"CPMP\/ICH\/286\/95. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions (E1). Geneva: European Medicines Agency; 1994."},{"key":"3690_CR17","volume-title":"Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2)","author":"CPMP\/ICH\/286\/95","year":"2008","unstructured":"CPMP\/ICH\/286\/95. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 (R2). Geneva: European Medicines Agency; 2008."},{"key":"3690_CR18","volume-title":"Evaluation of retroactive and adulticidal activity of moxidectin canine SR injectable formulation against Dirofilaria immitis infections in beagles","author":"J McCall","year":"2001","unstructured":"McCall J, Rulli R. Evaluation of retroactive and adulticidal activity of moxidectin canine SR injectable formulation against Dirofilaria immitis infections in beagles. Princeton: Fort Dodge Animal Health; 2001."},{"key":"3690_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.vetpar.2015.02.036","volume":"209","author":"J M\u00e9ndez","year":"2015","unstructured":"M\u00e9ndez J, Carret\u00f3n E, Mart\u00ednez-Subiela S, Tvarijonaviciute A, Cer\u00f3n J, Montoya-Alonso J. Acute phase protein response in heartworm-infected dogs after adulticide treatment. Vet Parasitol. 2015;209:197\u2013201.","journal-title":"Vet Parasitol."},{"key":"3690_CR20","volume-title":"Current canine guidelines for the prevention, diagnosis, and management of heartworm (Dirofilaria immitis) infection in dogs","author":"CT Nelson","year":"2018","unstructured":"Nelson CT, McCall JW, Jones S, Moorhead A. Current canine guidelines for the prevention, diagnosis, and management of heartworm (Dirofilaria immitis) infection in dogs. Wilmington: American Heartworm Society; 2018."},{"key":"3690_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13071-017-2190-9","volume":"10","author":"MD Savadelis","year":"2017","unstructured":"Savadelis MD, Ohmes CM, Hostetler JA, Settje TL, Zolynas R, Dzimianski MT, et al. Assessment of parasitological findings in heartworm-infected beagles treated with Advantage Multi\u00ae for dogs (10% imidacloprid\u00a0+\u00a02.5% moxidectin) and doxycycline. Parasites Vectors. 2017;10:245.","journal-title":"Parasites Vectors"},{"key":"3690_CR22","unstructured":"Dillon R, Warner A, Cox N, Brawner W, Blagburn B, Tillson M, et al. Cardiopulmonary effects of D. immitis byproducts in circulation in dogs, cats, and rats. In: 15th Triennial Heartworm Symposium. September 11\u201313, 2016. New Orleans: American Heartworm Society; 2016."},{"key":"3690_CR23","volume-title":"ProHeart\u00ae 12 (moxidectin) sustained release injection: injection site review and image analysis","author":"KJ Esch","year":"2016","unstructured":"Esch KJ. ProHeart\u00ae 12 (moxidectin) sustained release injection: injection site review and image analysis. Kalamazoo: Zoetis Veterinary Medicine; 2016."},{"key":"3690_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/0192623307309926","volume":"36","author":"J Schuh","year":"2008","unstructured":"Schuh J. Medical device regulations and testing for toxicologic pathologists. Toxicol Pathol. 2008;36:63\u20139.","journal-title":"Toxicol Pathol."},{"key":"3690_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ejpb.2013.07.017","volume":"85","author":"P Christophersen","year":"2013","unstructured":"Christophersen P, Zhang L, Yang M, Nielsen H, Mullertz A, Mu H. Solid lipid particles for oral delivery of peptide and protein drugs I. Elucidating the release mechanism of lysozyme during lipolysis. Eur J Pharm Biopharm. 2013;85:473\u201380.","journal-title":"Eur J Pharm Biopharm."},{"key":"3690_CR26","first-page":"2014","volume-title":"Safety Profile (01 June 2008 to 31 December 2013). Product: ProHeart SR 12 dated August 26, 2014","author":"TR Morton","year":"2014","unstructured":"Morton TR, Nederveld SM. Safety Profile (01 June 2008 to 31 December 2013). Product: ProHeart SR 12 dated August 26, 2014. Kalamazoo: Zoetis; 2014. p. 2014."},{"key":"3690_CR27","first-page":"241","volume-title":"Immunotoxicology strategies for pharmaceutical safety assessment","author":"R Pieters","year":"2008","unstructured":"Pieters R. Systemic hypersensitivity. In: Herzyk DJ, Bussiere JL, editors. Immunotoxicology strategies for pharmaceutical safety assessment. 1st ed. Hoboken: Wiley; 2008. p. 241\u201356.","edition":"1"},{"key":"3690_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/9781444322958.ch12","volume-title":"Veterinary pharmacovigilance adverse reactions to veterinary medicinal products","author":"TM Hodge","year":"2009","unstructured":"Hodge TM. Pharmacovigilance in the US\u2014an industry perspective. In: Woodward KN, editor. Veterinary pharmacovigilance adverse reactions to veterinary medicinal products. Chichester: Blackwell Publishing Ltd; 2009. p. 231\u201385."},{"key":"3690_CR29","first-page":"138","volume":"15","author":"V Lagopoulos","year":"2011","unstructured":"Lagopoulos V, Gigi E. Anaphylactic and anaphylactoid reactions during the perioperative period. Hippokratia. 2011;15:138\u201340.","journal-title":"Hippokratia."},{"key":"3690_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jaci.2013.04.038","volume":"132","author":"S-Y Yoon","year":"2013","unstructured":"Yoon S-Y, Baek S, Kim S, Lee Y, Lee T, Bae Y-J, et al. Serum procalcitonin as a biomarker differentiating delayed-type drug hypersensitivity from systemic bacterial infection. J Allergy Clin Immunol. 2013;132:981\u20133.","journal-title":"J Allergy Clin Immunol."},{"key":"3690_CR31","first-page":"49","volume":"3","author":"L Glickman","year":"2005","unstructured":"Glickman L, Glickman N, Moore G, Cobb R, Connell S, Morrison M, et al. Safety profile of moxidectin (ProHeart\u00ae 6) and two oral heartworm preventives in dogs. Int J Appl Res Vet Med. 2005;3:49\u201361.","journal-title":"Int J Appl Res Vet Med."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-019-3690-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T23:15:28Z","timestamp":1599261328000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-019-3690-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1186\/s13071-019-3690-6","relation":{},"ISSN":["1756-3305"],"issn-type":[{"type":"electronic","value":"1756-3305"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"3 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Studies 1\u20133 were conducted in accordance with United States Food and Drug Administration Good Laboratory Practice regulations for nonclinical studies and with applicable target animal safety guidelines (FDA Guidance for Industry #185 (study 1) or #33 (studies 2 and 3). Studies 4 and 5 were conducted in compliance with VICH GL9. All <i>in vivo<\/i> work was completed after ethical review and in full compliance with applicable local, state, national, and international animal welfare regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MJK, SM, AF, WC, TLW, KE, LL, TM, KA, EM, SN, KK, RC and JFB are current or former employees of Zoetis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"433"}}